Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine

A. J. Flach, L. M. Jampol, D. Weinberg, M. C. Kraff, L. A. Yannuzzi, R. V. Campo, A. C. Neumann, H. P. Cupples, W. H. Lefler, Jose S Pulido, C. Lavelle

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

Ketorolac tromethamine 0.5% ophthalmic solution treatment was compared to placebo treatment in 120 patients with chronic aphakic or pseudophakic cystoid macular edema (six-month or more duration of distance visual acuity of 20/40 or less and angiographic evidence of cystoid changes) during a four-to five-month double-masked, multicenter study in which patients were randomly assigned. A statistically significant improvement in distance visual acuity (two lines or more) was observed in the ketorolac-treated group as compared to the placebo-treated group after 30 days (P = .038), 60 days (P = .017), and 90 days (P = .008) of treatment. This improvement in visual acuity remained statistically significant one month after cessation of treatment (P = .001). Nine ketorolac-treated patients and two placebo-treated patients demonstrated a decrease in visual acuity one month after treatment was discontinued. Seven of the nine ketorolac-treated patients experienced an improvement in visual acuity after retreatment as compared to none of the placebo-treated patients. This study offers evidence for a more optimistic outlook in the medical treatment of chronic aphakic and pseudophakic cystoid macular edema.

Original languageEnglish (US)
Pages (from-to)514-519
Number of pages6
JournalAmerican Journal of Ophthalmology
Volume112
Issue number5
StatePublished - 1991
Externally publishedYes

Fingerprint

Ketorolac Tromethamine
Macular Edema
Visual Acuity
Ketorolac
Placebos
Therapeutics
Withholding Treatment
Retreatment
Ophthalmic Solutions
Double-Blind Method
Multicenter Studies

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Flach, A. J., Jampol, L. M., Weinberg, D., Kraff, M. C., Yannuzzi, L. A., Campo, R. V., ... Lavelle, C. (1991). Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. American Journal of Ophthalmology, 112(5), 514-519.

Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. / Flach, A. J.; Jampol, L. M.; Weinberg, D.; Kraff, M. C.; Yannuzzi, L. A.; Campo, R. V.; Neumann, A. C.; Cupples, H. P.; Lefler, W. H.; Pulido, Jose S; Lavelle, C.

In: American Journal of Ophthalmology, Vol. 112, No. 5, 1991, p. 514-519.

Research output: Contribution to journalArticle

Flach, AJ, Jampol, LM, Weinberg, D, Kraff, MC, Yannuzzi, LA, Campo, RV, Neumann, AC, Cupples, HP, Lefler, WH, Pulido, JS & Lavelle, C 1991, 'Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine', American Journal of Ophthalmology, vol. 112, no. 5, pp. 514-519.
Flach, A. J. ; Jampol, L. M. ; Weinberg, D. ; Kraff, M. C. ; Yannuzzi, L. A. ; Campo, R. V. ; Neumann, A. C. ; Cupples, H. P. ; Lefler, W. H. ; Pulido, Jose S ; Lavelle, C. / Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. In: American Journal of Ophthalmology. 1991 ; Vol. 112, No. 5. pp. 514-519.
@article{a66068cbba3d426cab242935f66704d3,
title = "Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5{\%} ketorolac tromethamine",
abstract = "Ketorolac tromethamine 0.5{\%} ophthalmic solution treatment was compared to placebo treatment in 120 patients with chronic aphakic or pseudophakic cystoid macular edema (six-month or more duration of distance visual acuity of 20/40 or less and angiographic evidence of cystoid changes) during a four-to five-month double-masked, multicenter study in which patients were randomly assigned. A statistically significant improvement in distance visual acuity (two lines or more) was observed in the ketorolac-treated group as compared to the placebo-treated group after 30 days (P = .038), 60 days (P = .017), and 90 days (P = .008) of treatment. This improvement in visual acuity remained statistically significant one month after cessation of treatment (P = .001). Nine ketorolac-treated patients and two placebo-treated patients demonstrated a decrease in visual acuity one month after treatment was discontinued. Seven of the nine ketorolac-treated patients experienced an improvement in visual acuity after retreatment as compared to none of the placebo-treated patients. This study offers evidence for a more optimistic outlook in the medical treatment of chronic aphakic and pseudophakic cystoid macular edema.",
author = "Flach, {A. J.} and Jampol, {L. M.} and D. Weinberg and Kraff, {M. C.} and Yannuzzi, {L. A.} and Campo, {R. V.} and Neumann, {A. C.} and Cupples, {H. P.} and Lefler, {W. H.} and Pulido, {Jose S} and C. Lavelle",
year = "1991",
language = "English (US)",
volume = "112",
pages = "514--519",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine

AU - Flach, A. J.

AU - Jampol, L. M.

AU - Weinberg, D.

AU - Kraff, M. C.

AU - Yannuzzi, L. A.

AU - Campo, R. V.

AU - Neumann, A. C.

AU - Cupples, H. P.

AU - Lefler, W. H.

AU - Pulido, Jose S

AU - Lavelle, C.

PY - 1991

Y1 - 1991

N2 - Ketorolac tromethamine 0.5% ophthalmic solution treatment was compared to placebo treatment in 120 patients with chronic aphakic or pseudophakic cystoid macular edema (six-month or more duration of distance visual acuity of 20/40 or less and angiographic evidence of cystoid changes) during a four-to five-month double-masked, multicenter study in which patients were randomly assigned. A statistically significant improvement in distance visual acuity (two lines or more) was observed in the ketorolac-treated group as compared to the placebo-treated group after 30 days (P = .038), 60 days (P = .017), and 90 days (P = .008) of treatment. This improvement in visual acuity remained statistically significant one month after cessation of treatment (P = .001). Nine ketorolac-treated patients and two placebo-treated patients demonstrated a decrease in visual acuity one month after treatment was discontinued. Seven of the nine ketorolac-treated patients experienced an improvement in visual acuity after retreatment as compared to none of the placebo-treated patients. This study offers evidence for a more optimistic outlook in the medical treatment of chronic aphakic and pseudophakic cystoid macular edema.

AB - Ketorolac tromethamine 0.5% ophthalmic solution treatment was compared to placebo treatment in 120 patients with chronic aphakic or pseudophakic cystoid macular edema (six-month or more duration of distance visual acuity of 20/40 or less and angiographic evidence of cystoid changes) during a four-to five-month double-masked, multicenter study in which patients were randomly assigned. A statistically significant improvement in distance visual acuity (two lines or more) was observed in the ketorolac-treated group as compared to the placebo-treated group after 30 days (P = .038), 60 days (P = .017), and 90 days (P = .008) of treatment. This improvement in visual acuity remained statistically significant one month after cessation of treatment (P = .001). Nine ketorolac-treated patients and two placebo-treated patients demonstrated a decrease in visual acuity one month after treatment was discontinued. Seven of the nine ketorolac-treated patients experienced an improvement in visual acuity after retreatment as compared to none of the placebo-treated patients. This study offers evidence for a more optimistic outlook in the medical treatment of chronic aphakic and pseudophakic cystoid macular edema.

UR - http://www.scopus.com/inward/record.url?scp=0025946584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025946584&partnerID=8YFLogxK

M3 - Article

C2 - 1951587

AN - SCOPUS:0025946584

VL - 112

SP - 514

EP - 519

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 5

ER -